We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
251
CALL
Immunovant
IMVT
$8.25B
– –
-10,200
Closed -$291K
INBS icon
252
Intelligent Bio Solutions
INBS
$4.74M
– –
-539
Closed -$9.32K
IONS icon
253
Ionis Pharmaceuticals
IONS
$9.4B
– –
-700
Closed -$28K
JSPR icon
254
Jasper Therapeutics
JSPR
$23.6M
– –
-15,816
Closed -$297K
JWN
255
DELISTED
Nordstrom
JWN
– –
-2,000
Closed -$45K
KROS icon
256
CALL
Keros Therapeutics
KROS
$221M
– –
-300
Closed -$17.4K
KRYS icon
257
Krystal Biotech
KRYS
$9.66B
– –
-100
Closed -$18.2K
KURA icon
258
Kura Oncology
KURA
$850M
– –
-30,000
Closed -$586K
LABD icon
259
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$57.2M
– –
-840
Closed -$49.1K
LQDA icon
260
Liquidia Corp
LQDA
$8.02B
– –
-9,285
Closed -$92.8K
MASI
261
DELISTED
Masimo
MASI
– –
-3,894
Closed -$519K
MCK icon
262
CALL
McKesson
MCK
$101B
– –
-3,000
Closed -$1.48M
MCK icon
263
McKesson
MCK
$101B
– –
-1,850
Closed -$915K
MDGL icon
264
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-50
Closed -$10.6K
MIST icon
265
Milestone Pharmaceuticals
MIST
$152M
– –
-27,931
Closed -$42.5K
MIRM icon
266
Mirum Pharmaceuticals
MIRM
$6.14B
– –
-24,100
Closed -$940K
MITK icon
267
Mitek Systems
MITK
$834M
– –
-200
Closed -$1.73K
MRKR icon
268
Marker Therapeutics
MRKR
$18.7M
– –
-2,432
Closed -$6.86K
MRVI icon
269
Maravai LifeSciences
MRVI
$919M
– –
-700
Closed -$5.82K
NATL icon
270
NCR Atleos
NATL
$3.44B
– –
-1,000
Closed -$28.5K
NGNE icon
271
Neurogene
NGNE
$712M
– –
-553
Closed -$23.2K
NTLA icon
272
Intellia Therapeutics
NTLA
$1.67B
– –
-800
Closed -$16.4K
NUVL
273
DELISTED
Nuvalent
NUVL
– –
-10,442
Closed -$1.07M
NVNO
274
enVVeno Medical
NVNO
$7.08M
– –
-9,950
Closed -$1.17M
NVO
275
CALL
Novo Nordisk
NVO
$209B
– –
-10,000
Closed -$1.19M
9 10
11
12 13

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.